Inhibiting a particular protein in cancer-killing immune cells might improve the long-term effectiveness of CAR T-cell and other immune checkpoint therapies, according to a new study by researchers at The Ohio State University ...
Jan 24, 2023
0
53
The recent years have seen a wave of adoptive cell therapies (ACTs), a type of immunotherapy in which T cells (T cell transfer therapy) and other immune cells are obtained from patients, activated and multiplied outside the ...
Jan 10, 2023
0
53
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types ...
Jan 9, 2023
0
35
Teaching the body's immune cells to recognize and fight cancer is one of the holy grails in medicine. Over the past two decades, researchers have developed new immunotherapy drugs that stimulate a patient's immune cells to ...
Dec 16, 2022
0
3
The Shin Kaneko laboratory at CiRA has developed a method to generate CAR-T cells from iPS cells (iCAR-T cells) that possess vastly improved anti-tumor activity in a mouse model of solid tumors.
Dec 13, 2022
0
8
Although immunotherapy has revolutionized the treatment of many blood cancers, the field has encountered challenges developing similar treatments for solid tumors. When it comes to pediatric brain tumors, which are the leading ...
Nov 1, 2022
0
6
A new approach to cancer immunotherapy that uses one type of immune cell to kill another—rather than directly attacking the cancer—provokes a robust anti-tumor immune response that shrinks ovarian, lung, and pancreatic ...
Oct 25, 2022
0
89
In the war against cancer, one of the most critical battles is waged on a cellular level as T cells from the immune system are altered in the lab to attack cancer cells. This form of immunotherapy, called chimeric antigen ...
Aug 25, 2022
0
69
Like the hardiest weed, glioblastoma almost always springs back—usually within months after a patient's initial brain tumor is surgically removed. That is why survival rates for this cancer are just 25 percent at one year ...
Aug 8, 2022
0
1770
T cells are usually good at eliminating diseased cells, but they seem to fail when it comes to tumor cells. In JCI Insight, MDC teams led by Armin Rehm and Uta Höpken describe what inhibits this immune function, and how ...
Jun 13, 2022
0
21
